{"id":"artesunate-mefloquine-as-mq","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Nausea and vomiting"},{"rate":"5-20","effect":"Dizziness and vertigo"},{"rate":"5-15","effect":"Neuropsychiatric effects (anxiety, insomnia, nightmares)"},{"rate":"5-15","effect":"Abdominal pain"},{"rate":"5-10","effect":"Headache"},{"rate":null,"effect":"Cardiac arrhythmias (rare)"}]},"_chembl":{"chemblId":"CHEMBL361497","moleculeType":"Small molecule","molecularWeight":"384.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Artesunate, a semi-synthetic artemisinin derivative, is activated by heme iron in parasites to form reactive oxygen species that cause oxidative damage to parasite proteins and nucleic acids. Mefloquine is a quinoline antimalarial that concentrates in the parasite's food vacuole and interferes with heme detoxification and membrane integrity. The combination provides rapid parasite clearance (artesunate) with extended post-treatment suppression (mefloquine), reducing recrudescence and transmission.","oneSentence":"Artesunate and mefloquine are antimalarial agents that work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while mefloquine disrupts parasite membrane function and metabolism.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:37.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Uncomplicated malaria caused by Plasmodium falciparum"},{"name":"Malaria caused by Plasmodium vivax, ovale, and malariae"}]},"trialDetails":[{"nctId":"NCT03923725","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combina-tions of 2 Anti-malarial Drugs.","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2020-09-01","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":2583},{"nctId":"NCT05690841","phase":"PHASE3","title":"FocaL Mass Drug Administration for Vivax Malaria Elimination","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2024-10-14","conditions":"Plasmodium Vivax Malaria, Malaria","enrollment":7530},{"nctId":"NCT03939104","phase":"PHASE3","title":"A Trial to Compare the Efficacy, Safety and Tolerability of Combinations of 3 Anti-malarial Drugs Against Combinations of 2 Anti-malarial Drugs (Asia)","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2021-06-30","conditions":"Plasmodium Falciparum Malaria (Uncomplicated)","enrollment":103},{"nctId":"NCT05052502","phase":"NA","title":"Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand","status":"UNKNOWN","sponsor":"University of California, San Francisco","startDate":"2020-11-01","conditions":"Plasmodium Falciparum Malaria, Plasmodium Vivax Malaria","enrollment":49118},{"nctId":"NCT02612545","phase":"PHASE1","title":"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-11-20","conditions":"Acute Falciparum Malaria","enrollment":216},{"nctId":"NCT01976780","phase":"PHASE4","title":"In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy","status":"COMPLETED","sponsor":"Global Emerging Infections Surveillance and Response System","startDate":"2013-06","conditions":"Malaria","enrollment":118},{"nctId":"NCT00852423","phase":"PHASE3","title":"Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2010-06","conditions":"Malaria in Pregnancy","enrollment":3428},{"nctId":"NCT02052323","phase":"PHASE4","title":"Harmonized AS/MQ Efficacy Study - Thailand","status":"COMPLETED","sponsor":"Armed Forces Research Institute of Medical Sciences, Thailand","startDate":"2013-10","conditions":"Malaria","enrollment":48},{"nctId":"NCT01319448","phase":"PHASE1, PHASE2","title":"Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2011-09","conditions":"Malaria, Sickle Cell Crisis","enrollment":270},{"nctId":"NCT01939886","phase":"PHASE3","title":"Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2)","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2013-04","conditions":"Malaria","enrollment":219},{"nctId":"NCT00701961","phase":"PHASE2, PHASE3","title":"Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2008-10","conditions":"Plasmodium Falciparum Malaria","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mequin"],"phase":"marketed","status":"active","brandName":"Artesunate/mefloquine (AS/MQ)","genericName":"Artesunate/mefloquine (AS/MQ)","companyName":"Armed Forces Research Institute of Medical Sciences, Thailand","companyId":"armed-forces-research-institute-of-medical-sciences-thailand","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Artesunate and mefloquine are antimalarial agents that work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while mefloquine disrupts parasite membrane function and metabolism. Used for Uncomplicated malaria caused by Plasmodium falciparum, Malaria caused by Plasmodium vivax, ovale, and malariae.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}